Descriptive only
Level 2 or 3 hypoglycemia (participants)
Type 2 diabetes (adults)
longest follow-upRecorded harmsDoses of a drug pooledHazard ratio (from event counts)Separate part 3 of a disconnected network
2
Randomized trials
3
Treatments
898
Participants
12
Events
In plain language
No network meta-analysis was fitted here. The protocol requires at least two trials forming a connected network; this outcome has 2 trials. The trial data below are shown as reported.
Network of trials
Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.
Baseline characteristics of the trials
The baseline value of each effect modifier or prognostic factor that applies here, per trial: mean or percent over arms, weighted by the number randomized. A note under a value names a stand in (a median for a mean, 100 minus the male share, Asian subgroup rows, an all Asian site list); "not reported" means no source of the trial prints it.
| Trial | Baseline HbA1c (percent) effect modifier, prognostic factor; 2 of 2 | Background glucose lowering therapy (stratum S0 to S4) effect modifier, prognostic factor; 2 of 2 |
|---|---|---|
| NCT06589765 S000558 | 8.6 | S1 |
| S003009 S003009 | 8.31 | S4 |
Comparability of the trials
Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.
- FlagBaseline, Background glucose lowering therapy: each design has a different category: DAPAGLIFLOZIN vs PEGLOX_SC = S4; DAPAGLIFLOZIN vs SAFIGL_PO = S1
- FlagOutcome assessment, analysis set: confounded with design: completers 1, safety 1
- FlagRisk of bias, blinding: confounded with design: double_blind 1, open_label 1
- NoteOutcome assessment, time point: selected time points span 24 to 52 weeks
- NoteData handling, input conversions: arms_combined 1
| Trial | time weeks | analysis set | definition | instrument | adjudicated | proportion method | intercurrent events (discontinuation) | intercurrent events (rescue) | blinding | funding | start year | Eligibility |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06589765 | 52 | safety | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2024 | age 18 to 75; HbA1c 7.5 to 11.0 percent; BMI 19 to 40; metformin monotherapy; eGFR 45 or more |
| S003009 | 24 | completers | not stated | not stated | not stated | not stated | not stated | not stated | open_label | industry | 2023 | age 18 or more; HbA1c 7.0 to 10.0 percent; eGFR 30 to 90; UACR above 30 to 5000 mg/g |
Trial data
What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the hazard ratio (from event counts) on the analysis scale (log) against the trial's first row. Flags mark converted, combined or approximated inputs.
| Trial | Arm | Treatment | Week | Data | Value | SE | Events / N | Flags | Source |
|---|---|---|---|---|---|---|---|---|---|
| NCT06589765 | A1+A2+A3 | SAFIGL_PO | 52 | arm, events | 10 / 608 | arms_combined | R0029347:Table 3 | ||
| NCT06589765 | A4 | DAPAGLIFLOZIN | 52 | arm, events | 0 / 202 | R0029347:Table 3 | |||
| S003009 | A1 | PEGLOX_SC | 24 | arm, events | 1 / 44 | R0011381:Table 4 | |||
| S003009 | A2 | DAPAGLIFLOZIN | 24 | arm, events | 1 / 44 | R0011381:Table 4 |
Rerun this analysis yourself
Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.